Tambor V, Fučíková A, Lenco J, Kacerovský M, Řeháček V, Stulík J, Pudil R
Institute of Molecular Pathology, Faculty of Military Health Sciences, University of Defence, Hradec Králové, Czech Republic.
Physiol Res. 2010;59(4):471-497. doi: 10.33549/physiolres.931758. Epub 2009 Nov 20.
Ever since proteomics was proven to be capable of characterizing a large number of differences in both protein quality and quantity, it has been applied in various areas of biomedicine, ranging from the deciphering molecular pathogenesis of diseases to the characterization of novel drug targets and the discovery of potential diagnostic biomarkers. Indeed, the biomarker discovery in human plasma is clearly one of the areas with enormous potential. However, without proper planning and implementation of specific techniques, the efforts and expectations may very easily be hampered. Numerous earlier projects aimed at clinical proteomics, characterized by exaggerated enthusiasm, often underestimated some principal obstacles of plasma biomarker discovery. Consequently, ambiguous and insignificant results soon led to a more critical view in this field. In this article, we critically review the current state of proteomic approaches for biomarker discovery and validation, in order to provide basic information and guidelines for both clinicians and researchers. These need to be closely considered prior to initiation of a project aimed at plasma biomarker discovery. We also present a short overview of recent applications of clinical proteomics in biomarker discovery.
自从蛋白质组学被证明能够表征蛋白质质量和数量方面的大量差异以来，它已被应用于生物医学的各个领域，从破解疾病的分子发病机制到表征新型药物靶点以及发现潜在的诊断生物标志物。事实上，在人血浆中发现生物标志物显然是具有巨大潜力的领域之一。然而，如果没有适当的规划和特定技术的实施，这些努力和期望很容易受到阻碍。许多早期针对临床蛋白质组学的项目，其特点是热情高涨，往往低估了血浆生物标志物发现的一些主要障碍。因此，模糊且无意义的结果很快导致了该领域更为批判性的观点。在本文中，我们批判性地回顾了用于生物标志物发现和验证的蛋白质组学方法的现状，以便为临床医生和研究人员提供基本信息和指导方针。在启动旨在发现血浆生物标志物的项目之前，需要仔细考虑这些内容。我们还简要概述了临床蛋白质组学在生物标志物发现中的最新应用。
